334970.Kq
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and biologics.
Business. The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and biologics.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and biologics.
The company's capital structure is characterized by a debt-to-equity ratio of 0.68, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.4, suggesting potential challenges in meeting short-term obligations. The price-to-book ratio of 1.15 implies that the market value is slightly above the book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium.
Profitability metrics reveal a challenging financial position. The company reported a net loss of 27,469,488,630 KRW, with a return on equity of -20.32% and a return on assets of -10.16%. These figures are below the industry median for profitability, as defined by the industry_config, and suggest a need for operational improvements to restore profitability.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset losses in one region with gains in another.
Growth trajectory is negative, with the company reporting a decline in revenue and profitability. The outlook for the current fiscal year indicates a continuation of this trend, with no significant improvement expected in the near term. Historical revenue data shows a consistent decline, reinforcing the bearish outlook.
Risk factors include a medium liquidity risk, driven by a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the near term. The company has not made any recent equity issuances or announced plans for additional share offerings, which supports the low dilution risk assessment.
Recent events include the filing of financial statements that highlight the company's ongoing financial challenges. No significant management changes or strategic shifts have been disclosed in recent transcripts or filings, suggesting a lack of immediate corrective actions.
- The company is experiencing significant financial losses, with a net loss of 27,469,488,630 KRW.
- The debt-to-equity ratio of 0.68 indicates a moderate reliance on debt financing.
- The company's liquidity position is assessed as medium, with a current ratio of 0.4.
- Profitability metrics are below industry medians, with a return on equity of -20.32%.
- The company's revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The outlook for the current fiscal year is bearish, with no significant improvement expected in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 334970.KQ Market data — financials · 2026-05-26